BeiGene | A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Beigene Study ID

BGB-A317-A3055-101

ClinicalTrials.gov ID

NCT05935098

EudraCT Number

2023-505322-34-00

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents